Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$18.83 -4.5%	$18.67	$13.52 ▼ $35.25	$1.98B	2.22	2.37 million shs	2.71 million shs
DNLI Denali Therapeutics	$13.44 -2.8%	$14.20	$10.57 ▼ $33.33	$2.01B	1.36	1.38 million shs	1.76 million shs
LEGN Legend Biotech	$38.80 -0.7%	$36.34	$27.34 ▼ $59.62	$7.18B	0.26	1.37 million shs	1.09 million shs
ROIV Roivant Sciences	$11.31 -0.4%	$11.27	$8.73 ▼ $13.06	$7.72B	1.15	4.91 million shs	2.91 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-4.46%	-13.31%	-5.28%	-6.97%	-40.49%
DNLI Denali Therapeutics	-2.82%	-1.68%	-9.80%	-18.25%	-44.85%
LEGN Legend Biotech	-0.69%	-10.52%	+8.05%	+16.97%	-31.19%
ROIV Roivant Sciences	-0.44%	-2.08%	+3.10%	-1.48%	+4.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.5839 of 5 stars	3.5	1.0	0.0	3.2	2.5	0.6
DNLI Denali Therapeutics	4.5689 of 5 stars	4.6	1.0	4.7	3.8	3.3	0.0
LEGN Legend Biotech	3.5818 of 5 stars	4.5	4.0	0.0	2.4	1.7	0.6
ROIV Roivant Sciences	1.8308 of 5 stars	3.6	1.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.75	158.90% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	151.83% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$73.33	89.00% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	45.89% Upside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, ROIV, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2025	LEGN Legend Biotech	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/17/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/10/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00 ➝ $81.00
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
7/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/2/2025	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00 ➝ $54.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	29.81	N/A	N/A	$8.86 per share	2.13
DNLI Denali Therapeutics	$330.53M	5.91	N/A	N/A	$8.53 per share	1.58
LEGN Legend Biotech	$627.24M	11.37	N/A	N/A	$5.70 per share	6.81
ROIV Roivant Sciences	$29.05M	264.64	N/A	N/A	$7.45 per share	1.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	8/7/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/11/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/11/2025 (Estimated)

Latest DNLI, BEAM, ROIV, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	LEGN Legend Biotech	-$0.18	N/A	N/A	N/A	$237.49 million	N/A
8/11/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	$6.92 million	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	$5.64 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
DNLI Denali Therapeutics	N/A	9.56	9.56
LEGN Legend Biotech	0.30	5.20	5.07
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
LEGN Legend Biotech	70.89%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
DNLI Denali Therapeutics	12.50%
LEGN Legend Biotech	0.02%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

DNLI, BEAM, ROIV, and LEGN Headlines

Recent News About These Companies

XTX Topco Ltd Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 30 at 5:27 AM | marketbeat.com

Skandinaviska Enskilda Banken AB publ Has $751,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 30 at 5:27 AM | marketbeat.com

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 28, 2025 | globenewswire.com

Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating

July 25, 2025 | msn.com

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells $1,152,000.00 in Stock

July 25, 2025 | americanbankingnews.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Sells 100,000 Shares of Stock

July 24, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker Sells 100,000 Shares

July 24, 2025 | insidertrades.com

New York State Common Retirement Fund Sells 28,400 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

July 24, 2025 | marketbeat.com

Mutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

July 20, 2025 | marketbeat.com

CenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 16, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 15, 2025 | marketbeat.com

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?

July 9, 2025 | marketbeat.com

DAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 9, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

July 9, 2025 | marketbeat.com

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28, 2025 | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, ROIV, and LEGN Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$18.83 -0.88 (-4.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$18.98 +0.15 (+0.80%)

As of 08/1/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$13.44 -0.39 (-2.82%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.36 -0.08 (-0.63%)

As of 08/1/2025 07:50 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Legend Biotech NASDAQ:LEGN

$38.80 -0.27 (-0.69%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.03%)

As of 08/1/2025 07:45 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Roivant Sciences NASDAQ:ROIV

$11.31 -0.05 (-0.44%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$11.04 -0.28 (-2.43%)

As of 08/1/2025 06:11 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time